Klaus F. Rabe, Academic

Klaus F. Rabe: key facts

Kind of voice: Academic
Role: Presenter of AERIFY-1 and AERIFY-2 trials at ATS International Conference 2026
Quoted on: Respiratory (asthma/COPD)
Tracked press citations: 1
Most recently quoted: 30 Sept 2026

“Klaus F. Rabe et al. Efficacy and Safety of Itepekimab in Former Smokers With Chronic Obstructive Pulmonary Disease: AERIFY-1 and AERIFY-2 Trials. ATS International Conference, 2026.”
on Respiratory (asthma/COPD) · 30 Sept 2026 · Read the article ↗

Where Klaus F. Rabe has been quoted

ATS 2026: Itepekimab COPD Trial Shows Mixed Resultsemjreviews.com · 30 Sept 2026

Related media coverage

Recent UK press coverage of their topics — not necessarily citing them directly.

Household e-cigarette exposure linked to poorer asthma control in childrenContemporary Pediatrics
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trialsPharmafile
Lung cancer is India’s deadliest cancer. So why don’t we screen for it?The Indian Express

Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.